Surface modification of lipid-based nanocarriers for cancer cellspecific drug targeting

다국어 초록 (Multilingual Abstract)

Targeted drug delivery systems using nanocarriers for anticancer drugs have been investigated for over several decades. Among the many nanocarrier systems, lipid-based nanocarriers such as liposomes, solid lipid nanoparticles, and nanostructured lipid carriers have afforded attention as a carrier system to improve the efficacy of anticancer drugs. Recent efforts have focused on cancer cellspecific drug delivery through the functionalization of the surface of lipid-based nanocarriers with various ligands such as targeting moieties, cell-penetrating peptides, and cell-penetrating homing peptides to overcome non-selectivity, minimize side effects, and enhance antitumor efficacy.
However, the use of ligand modification has been limited because the nanocarriers were easily recognized by the mononuclear phagocyte system and thus rapidly removed from the blood circulation. To achieve prolonged systemic circulation, nanocarriers were further modified with protective polymers such as polyethylene glycol (PEG).
Unexpectedly, this presented a PEG dilemma, as the interaction of ligands with the target was hindered and induced poor cellular uptake. Recently, stimuli-sensitive cleavage of the PEG coat, following recognition of the cancer cell microclimate, such as low pH, redox-potential, and overexpressed enzymes, was established to solve this problem.
This review presents a comprehensive overview on the current state of surface-modified lipid-based nanocarriers for the improved delivery of anticancer drugs.

참고문헌 (Reference)

• 1 Chen D, "pH-sensitive mPEG-Hz-cholesterol conjugates as a liposome delivery system" 25 : 527-542, 2010
• 2 Kim HK, "pH-responsive biodegradable assemblies containing tunable phenyl-substituted vinyl ethers for use as efficient gene delivery vehicles" 5 : 5648-5658, 2013
• 3 Du J, "Which one performs better for targeted lung cancer combination therapy: pre-or post-bombesin-decorated nanostructured lipid carriers?" 23 : 1799-1809, 2016
• 4 Scherphof GL, "Uptake and intracellular processing of targeted and nontargeted liposomes by Rat Kupffer Cells in vivo and in vitro" 446 : 368-384, 1985
• 5 Zagar TM, "Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer" 30 : 285-294, 2014
• 6 Liu R, "Tumor-targeting peptides from combinatorial libraries" 2016
• 7 Yang ZZ, "Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas" 35 : 5226-5239, 2014
• 8 Goutayer M, "Tumor targeting of functionalized lipid nanoparticles:assessment by in vivo fluorescence imaging" 75 : 137-147, 2010
• 9 Liu D, "Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody" 8 : 2291-2301, 2011
• 10 Mo R, "Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery" 19 : 274-283, 2016
• 11 Han Y, "Transferrinmodified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin" 9 : 4107-4116, 2014
• 12 Muthu MS, "Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots" 33 : 3494-3501, 2012
• 13 Temsamani J, "The use of cell-penetrating peptides for drug delivery" 9 : 1012-1019, 2004
• 14 Gao J, "The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes" 32 : 3459-3470, 2011
• 15 Iyer AK, "The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma" 32 : 2605-2613, 2011
• 16 Duncan R, "The dawning era of polymer therapeutics" 2 : 347-360, 2003
• 17 Ishida T, "The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study" 7 : 286-286, 2002
• 18 Maeda H, "The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo" 65 : 71-79, 2013
• 19 Torchilin VP, "Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers" 60 : 548-558, 2008
• 20 Wicki A, "Targeting tumor-associated endothelial cells:anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth" 18 : 454-464, 2012
• 21 Xu S, "Targeting receptor-mediated endocytotic pathways with nanoparticles:rationale and advances" 65 : 121-138, 2013
• 22 Khajavinia A, "Targeting etoposide to acute myelogenous leukemia cells using nanostructured lipid carriers coated with transferrin" 23 : 1-13, 2012
• 23 Guo Z, "Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering" 35 : 6106-6117, 2014
• 24 Garg A, "Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide" 366 : 201-210, 2009
• 25 Sanna V, "Targeted therapy using nanotechnology:focus on cancer" 9 : 467-483, 2014
• 26 Ross JS, "Targeted therapies for cancer 2004" 122 : 598-609, 2004
• 27 Zheng J, "Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles" 31 : 2220-2233, 2014
• 28 Shao Z, "Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA" 10 : 1223-1233, 2015
• 29 Sudimack J, "Targeted drug delivery via the folate receptor" 41 : 147-162, 2000
• 30 Yuan M, "Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma" 23 : 1171-1183, 2016
• 31 Zhang S, "Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system" 23 : 1838-1845, 2016
• 32 Li X, "Targeted delivery of doxorubicin using stealth liposomes modified with transferrin" 373 : 116-123, 2009
• 33 Kuai R, "Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly (ethylene glycol) comodified liposomal delivery system via systemic administration" 8 : 2151-2161, 2011
• 34 Akhtar MJ, "Targeted anticancer therapy: overexpressed receptors and nanotechnology" 436 : 78-92, 2014
• 35 Hatakeyama H, "Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEGlipid" 32 : 4306-4316, 2011
• 36 Ucar E, "Synthesis, characterization and radiolabeling of folic acid modified nanostructured lipid carriers as a contrast agent and drug delivery system" 119 : 72-79, 2017
• 37 Negussie AH, "Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome" 143 : 265-273, 2010
• 38 Kwon YH, "Surface-modification of RIPL peptide-conjugated liposomes to achieve steric stabilization and pH sensitivity" 17 : 1008-1017, 2017
• 39 Biswas S, "Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity" 84 : 517-525, 2013
• 40 Wan F, "Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro" 359 : 104-110, 2008
• 41 Chou LY, "Strategies for the intracellular delivery of nanoparticles" 40 : 233-245, 2011
• 42 Du J, "Stimuli-responsive nanoparticles for targeting the tumor microenvironment" 219 : 205-214, 2015
• 43 Li SD, "Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting" 145 : 178-181, 2010
• 44 Immordino ML, "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential" 1 : 297-315, 2006
• 45 Dai W, "Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes" 29 : 2902-2911, 2012
• 46 Mehnert W, "Solid lipid nanoparticles: production, characterization and applications" 47 : 165-196, 2001
• 47 Wissing SA, "Solid lipid nanoparticles for parenteral drug delivery" 56 : 1257-1272, 2004
• 48 Müller RH, "Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations" 54 : S131-S155, 2002
• 49 Romberg B, "Sheddable coatings for long-circulating nanoparticles" 25 : 55-71, 2008
• 50 Jiang J, "Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin" 76 : 170-178, 2010
• 51 Zhang XG, "Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells" 361 : 239-244, 2008
• 52 Zhang Q, "Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response" 13 : 1800-1808, 2016
• 53 Hobbs SK, "Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment" 95 : 4607-4612, 1998
• 54 Oumzil K, "Reductiontriggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating" 151 : 123-130, 2011
• 55 Gordon AN, "Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan" 19 : 3312-3322, 2001
• 56 Fillebeen C, "Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier" 274 : 7011-7017, 1999
• 57 Gill PS, "Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma" 14 : 2353-2364, 1996
• 58 Sakurai Y, "RNAi-mediated gene knockdown and antiangiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system" 173 : 110-118, 2014
• 59 Kang MH, "RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells" 87 : 489-499, 2014
• 60 Chang M, "RGDmodified pH-sensitive liposomes for docetaxel tumor targeting" 129 : 175-182, 2015
• 61 Shan D, "RGDconjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells" 5 : 15-26, 2015
• 62 Benhabbour SR, "Protein resistance of PEG-functionalized dendronized surfaces: effect of PEG molecular weight and dendron generation" 41 : 4817-4823, 2008
• 63 Shehata T, "Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers" 359 : 272-279, 2008
• 64 Srinivasarao M, "Principles in the design of ligand-targeted cancer therapeutics and imaging agents" 14 : 203-219, 2015
• 65 Immordino ML, "Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel" 91 : 417-429, 2003
• 66 Üner M, "Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems" 61 : 375-386, 2006
• 67 Li X, "Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers" 61 : 1485-1492, 2009
• 68 Bao A, "Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection" 316 : 162-169, 2006
• 69 Fishman MN, "Phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer" 22 : 2110-2110, 2004
• 70 Gaillard PJ, "Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)" 9 : e82331-, 2014
• 71 Zara GP, "Pharmacokinetics and tissue distribution of idarubicinloaded solid lipid nanoparticles after duodenal administration to rats" 91 : 1324-1333, 2002
• 72 Accardo A, "Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent" 7 : 2007-2017, 2012
• 73 Cai L, "Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo" 7 : 4499-4510, 2012
• 74 Remaut K, "Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides" 117 : 256-266, 2007
• 75 Marasco D, "Past and future perspectives of synthetic peptide libraries" 9 : 447-467, 2008
• 76 Liu Y, "Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting" 35 : 4835-4847, 2014
• 77 Mishra S, "PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles" 83 : 97-111, 2004
• 78 Ginn C, "PEGylation and its impact on the design of new protein-based medicines" 6 : 1829-1846, 2014
• 79 Zhang X, "PEGylated nanostructured lipid carriers loaded with 10- hydroxycamptothecin: an efficient carrier with enhanced anti- tumour effects against lung cancer" 60 : 1077-1087, 2008
• 80 Vllasaliu D, "PEGylated nanomedicines:recent progress and remaining concerns" 11 : 139-154, 2014
• 81 Drummond DC, "Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors" 51 : 691-744, 1999
• 82 Owens DE, "Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles" 307 : 93-102, 2006
• 83 Iwase Y, "Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma" 8 : 330-337, 2011
• 84 Nakamura Y, "Octaargininemodified multifunctional envelope-type nano device for siRNA" 11 : 360-367, 2007
• 85 Biswas S, "Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer" 335 : 191-200, 2013
• 86 Chen Y, "Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells" 6 : 696-705, 2009
• 87 Song S, "Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy" 23 : 1404-1408, 2016
• 88 Terada T, "Novel PEG-matrix metalloproteinase-2 cleavable peptidelipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting" 111 : 333-342, 2006
• 89 Fundarò A, "Non-stealth and stealth solid lipid nanoparticles (SLN)carrying doxorubicin: pharmacokinetics and tissue distribution after iv administration to rats" 42 : 337-343, 2000
• 90 Sinha R, "Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery" 5 : 1909-1917, 2006
• 91 Müller RH, "Nanostructured lipid matrices for improved microencapsulation of drugs" 242 : 121-128, 2002
• 92 Bondì ML, "Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies" 14 : 61-67, 2007
• 93 Taratula O, "Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA" 171 : 349-357, 2013
• 94 Patel DK, "Nanostructured lipid carrier (NLC) a modern approach for topical delivery: a review" 2 : 921-938, 2013
• 95 Walkey CD, "Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake" 134 : 2139-2147, 2012
• 96 Brannon-Peppas L, "Nanoparticle and targeted systems for cancer therapy" 64 : 206-212, 2012
• 97 Wicki A, "Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications" 200 : 138-157, 2015
• 98 Torchilin VP, "Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery" 13 : 813-827, 2014
• 99 Liu Y, "Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma" 7 : 16792-16801, 2015
• 100 Torchilin VP, "Multifunctional and stimuli-sensitive pharmaceutical nanocarriers" 71 : 431-444, 2009
• 101 Koren E, "Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity" 160 : 264-273, 2012
• 102 Tavano L, "Multi-functional vesicles for cancer therapy: the ultimate magic bullet" 147 : 161-171, 2016
• 103 Al-Ahmady ZS, "Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia" 196 : 332-343, 2014
• 104 Lozano N, "Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent" 482 : 2-10, 2015
• 105 Gupta B, "Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice" 56 : 1215-1223, 2007
• 106 Zhu L, "Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting" 6 : 3491-3498, 2012
• 107 McNeeley KM, "Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors" 30 : 3986-3995, 2009
• 108 Jain A, "Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug" 148 : 359-367, 2010
• 109 Kulkarni PS, "MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer" 11 : 2390-2399, 2014
• 110 Gao J, "Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing" 31 : 2655-2664, 2010
• 111 He Y, "Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes" 5 : 697-705, 2010
• 112 Khalid MN, "Long circulating poly (ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors" 23 : 752-758, 2006
• 113 Qin Y, "Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals" 420 : 304-312, 2011
• 114 Qin Y, "Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery" 419 : 85-95, 2011
• 115 Joshi MD, "Lipid nanoparticles for parenteral delivery of actives" 71 : 161-172, 2009
• 116 Pardeike J, "Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products" 366 : 170-184, 2009
• 117 Chen H, "Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery" 40 : 94-102, 2010
• 118 Chen H, "Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas" 44 : 164-173, 2011
• 119 Iwamaru Y, "Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation" 107 : 636-646, 2008
• 120 Demeule M, "Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2" 106 : 1534-1544, 2008
• 121 Bruun J, "Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells" 10 : 5995-6008, 2015
• 122 Maruyama K, "Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects" 63 : 161-169, 2011
• 123 Mei L, "Increased tumor targeted delivery using a multistage liposome system functionalized with RGD TAT and cleavable PEG" 468 : 26-38, 2014
• 124 Koshkaryev A, "Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrinmodified liposomes" 13 : 50-60, 2012
• 125 Chen DB, "In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel" 49 : 1444-1447, 2001
• 126 Li X, "In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer modified liposomes loaded with docetaxel" 6 : 1167-1184, 2011
• 127 Yang G, "In vitro and in vivo antitumor effects of folate-targeted ursolic acid Stealth liposome" 62 : 2207-2215, 2014
• 128 Amin M, "Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas" 458 : 324-333, 2013
• 129 Chen X, "Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide" 145 : 17-25, 2010
• 130 Üner M, "Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives" 2 : 289-300, 2007
• 131 Bidlingmaier S, "Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma" 69 : 1570-1577, 2009
• 132 Perche F, "Hypoxia targeted siRNA delivery" 53 : 3362-3366, 2014
• 133 Cai D, "Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy" 35 : 2283-2294, 2014
• 134 Tran TH, "Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells" 114 : 407-415, 2014
• 135 Yang XY, "Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer" 334 : 338-345, 2013
• 136 Ravar F, "Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation" 229 : 10-22, 2016
• 137 Arpicco S, "Hyaluronic acid-coated liposomes for active targeting of gemcitabine" 85 : 373-380, 2013
• 138 Mattheolabakis G, "Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine" 23 : 605-618, 2015
• 139 Necas J, "Hyaluronic acid (hyaluronan): a review" 53 : 397-411, 2008
• 140 Landesman-Milo D, "Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells" 334 : 221-227, 2013
• 141 Zhang L, "High tumor penetration of paclitaxel loaded pH sensitive cleavable liposomes by depletion of tumor collagen I in breast cancer" 7 : 9691-9701, 2015
• 142 Shmeeda H, "Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage" 136 : 155-160, 2009
• 143 Wei M, "Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin" 46 : 131-141, 2012
• 144 Chen J, "Glucosamine derivative modified nanostructured lipid carriers for targeted tumor delivery" 22 : 5770-5783, 2012
• 145 Jain A, "Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin" 134 : 47-58, 2015
• 146 Cheng L, "GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation" 9 : 921-935, 2014
• 147 Kang MJ, "Folic acidtethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluation" 8 : 1155-1165, 2013
• 148 Leamon CP, "Folate-targeted chemotherapy" 56 (56): 1127-1141, 2004
• 149 Wu L, "Folate-mediated solid–liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol)" 36 : 439-448, 2010
• 150 Ye P, "Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting" 9 : 2167-2178, 2014
• 151 Zhu Y, "Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo" 31 : 3289-3330, 2014
• 152 Gullotti E, "Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery" 6 : 1041-1051, 2009
• 153 Brown JM, "Exploiting tumour hypoxia in cancer treatment" 4 : 437-447, 2004
• 154 Mohammadi Ghalaei P, "Evaluating cytotoxicity of hyaluronate targeted solid lipid nanoparticles of etoposide on SK-OV-3 cells" 7 : 1-7, 2014
• 155 Reddy LH, "Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies" 6 : 55-64, 2004
• 156 Paliwal SR, "Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy" 9 : 176-186, 2011
• 157 Wan Y, "Enzymeresponsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity" 34 : 3020-3030, 2013
• 158 De La Rica R, "Enzyme-responsive nanoparticles for drug release and diagnostics" 64 : 967-978, 2012
• 159 Hu Q, "Enzyme-responsive nanomaterials for controlled drug delivery" 6 : 12273-12286, 2014
• 160 Qu CY, "Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy" 10 : 3911-3920, 2015
• 161 Madhankumar AB, "Efficacy of interleukin-13 receptor–targeted liposomal doxorubicin in the intracranial brain tumor model" 8 : 648-654, 2009
• 162 Wang RH, "Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer" 33 : 783-791, 2015
• 163 Chen D, "Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon" 6 : 2053-2061, 2011
• 164 Kobayashi T, "Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells" 329 : 94-102, 2007
• 165 Su Z, "Effect of octreotide–polyethylene glycol (100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine" 8 : 1641-1651, 2011
• 166 Su Z, "Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization" 447 : 281-292, 2013
• 167 Gao J, "EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma" 33 : 270-282, 2012
• 168 Webb BA, "Dysregulated pH: a perfect storm for cancer progression" 11 : 671-677, 2011
• 169 Zhang X, "Dualfunctional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells" 33 : 7103-7114, 2012
• 170 Kibria G, "Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery" 153 : 141-148, 2011
• 171 Lammers T, "Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress" 161 : 175-187, 2012
• 172 Navarro G, "Drug delivery" Jones & Bartlett learning 157-187, 2014
• 173 Hong RL, "Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice" 5 : 3645-3652, 1999
• 174 Hatakeyama H, "Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid" 14 : 68-77, 2007
• 175 Kang MH, "Design of multifunctional liposomal nanocarriers for folate receptor-specific intracellular drug delivery" 12 : 4200-4213, 2015
• 176 Shmeeda H, "Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells" 146 : 76-83, 2010
• 177 Li Y, "Delivery of siRNA using lipid nanoparticles modified with cell penetrating peptide" 8 : 26613-26621, 2016
• 178 Furuhata M, "Decaarginine-PEG-liposome enhanced transfection efficiency and function of arginine length and PEG" 371 : 40-46, 2009
• 179 Mishra B, "Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery" 6 : 9-24, 2010
• 180 Shen H, "Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells" 5 : 755-771, 2015
• 181 Xu X, "Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer" 14 : 2591-2594, 2013
• 182 Hou C, "Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker" 33 : 203-209, 2006
• 183 Qhattal HSS, "Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronangrafted liposomes" 8 : 1233-1246, 2011
• 184 Gerweck LE, "Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer" 56 : 1194-1198, 1996
• 185 Trabulo S, "Cell-penetrating peptides—mechanisms of cellular uptake and generation of delivery systems" 3 : 961-993, 2010
• 186 Copolovici DM, "Cell-penetrating peptides: design, synthesis, and applications" 8 : 1972-1994, 2014
• 187 Santosh Bashyal, "Cell penetrating peptides as an innovative approach for drug delivery; then, present and the future" 한국약제학회 46 (46): 205-220, 2016
• 188 Bertrand N, "Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology" 66 : 2-25, 2014
• 189 Liu D, "Cancer chemotherapy with lipid-based nanocarriers" 27 : 371-417, 2010
• 190 Wang L, "CD44antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma" 33 : 5107-5114, 2012
• 191 Rodriguez BL, "Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model" 10 : 2404-2415, 2013
• 192 Yuan L, "Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model" 8 : 4339-4350, 2013
• 193 Kim IY, "Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice" 140 : 55-60, 2009
• 194 Luria-Pérez R, "Antibody-mediated targeting of the transferrin receptor in cancer cells" 73 : 372-379, 2016
• 195 Banerjee R, "Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells" 112 : 693-700, 2004
• 196 Chono S, "An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor" 131 : 64-69, 2008
• 197 Ding Y, "An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery" 10 : 6199-6214, 2015
• 198 Fan Zeng, "Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy" 한국약제학회 44 (44): 493-504, 2014
• 199 Dams ET, "Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes" 292 : 1071-1079, 2000
• 200 Sun M, "A systematic in vitro investigation on poly-arginine modified nanostructured lipid carrier: pharmaceutical characteristics, cellular uptake, mechanisms and cytotoxicity" 12 : 51-58, 2016
• 201 Steichen SD, "A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics" 48 : 416-427, 2013
• 202 Awada A, "A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)" 25 : 824-831, 2014
• 203 Mamot C, "A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors" 29 : 3029-3029, 2011
• 204 Sankhala KK, "A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin" 27 : 2535-, 2009
• 205 Zhang J, "A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models" 7 : 1159-1168, 2010
• 206 Paliwal SR, "A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy" 10 : 343-353, 2010
• 207 Shi C, "A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: physical characterization and cellular uptake evaluation in vitro and in vivo" 69 : 191-200, 2015
• 208 Mansour AM, "A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2" 63 : 4062-4066, 2003
• 209 Ko AH, "A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer" 109 : 920-925, 2013
• 210 Tang J, "A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes" 4 : 67-73, 2014